| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Emily Bodnar reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $8 pr...
Xanthopoulos succeeds Wubin (Bill) Pan, who will remain on the Board and serve as an advisor to the Company during the transiti...
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and susta...
HC Wainwright & Co. analyst Emily Bodnar maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and raises the price...
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(1.08) per share. This is a 49.77 percent increase over los...
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating a...
